(UroToday.com) The joint session of the European Association of Urology (EAU) and the Canadian Urological Association (CUA) included a presentation by Dr. Antonio Finelli discussing the importance of making indications for prostate biopsy as precise as possible. Dr. Finelli notes that the question of who and how we should biopsy men is a difficult question to address. Looking at the Canadian guidelines, screening is broadly based on PSA level with adjunctive testing and prostate biopsy considered in those with an elevated PSA >3 ng/ml, based on the threshold of 3 ng/mL in the ERSPC trial and 2.5-3.4 ng/mL in the Goteborg trial. As follows is the algorithm from the CUA guidelines: